Larotinib
Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM[1].
Product Specifications
CAS Number
1438072-11-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Btk; EGFR; IRAK
Type
Reference compound
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/larotinib.html
Purity
99.50
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
COC(C(OCCCN1C[C@]2([H])[C@](OCCO2)([H])C1)=C3)=CC4=C3C(NC5=CC(Cl)=C(C=C5)F)=NC=N4
Molecular Formula
C24H26ClFN4O4
Molecular Weight
488.94
Precautions
H302, H315, H319
References & Citations
[1]Liu J, et al. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol. 2021 Feb 18;12:636324.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2; ErbB4/HER4; IRAK1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
